Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Iberdomide · Zenbexus, CC-220

Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN), Aiolos (IKZF3) and Ikaros (IKZF1) · developed by Bristol Myers Squibb

Approved FDA, Aug 2026
BMY Developer

What is Iberdomide?

Iberdomide is a cereblon-modulating protein degrader that binds cereblon, a substrate receptor of an E3 ubiquitin ligase, and promotes ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros. It is studied in multiple myeloma, including refractory disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zenbexus, CC-220, BMS-986382, C25H28N3O5Cl
Drug type
Small molecule (Molecular glue degrader)
Targets
cereblon (CRBN), Aiolos (IKZF3), Ikaros (IKZF1)
Mechanism
Degrader of cereblon (CRBN), Aiolos (IKZF3) and Ikaros (IKZF1)
Pathways
E3 ubiquitin ligase-mediated proteasomal degradation, IL-2 and IFN-gamma cytokine secretion, T-cell exhaustion prevention, daratumumab CDC and ADCC enhancement
Therapy area
Oncology
Developer
Bristol Myers Squibb (BMY)
FDA status
Approved as Zenbexus (August 13, 2026), NDA221075 · FDA label
UNII
8V66F27X44

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 13, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Multiple MyelomaMyelomaRefractory Multiple Myeloma

Other drugs acting on CRBN / IKZF3 / IKZF1

More from Bristol Myers Squibb

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Iberdomide

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.